ASH 2021 | Developing a comprehensive multiple myeloma targeted genomic sequencing panel
Sarah Gooding, MD PhD, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, talks on the development of a comprehensive multiple myeloma targeted genomic sequencing panel. Multiple myeloma is genetically heterogenous, with numerous alterations well known to impact patient risk and outcomes, as well as rare, potentially targetable mutations. The panel was designed to detect all major genetic changes that are frequently mutated, associated with prognosis or risk stratification, clinically actionable, or sites of important copy number abnormalities. Testing and validation of the panel showed it to perform as well as or better than FISH and whole genome sequencing techniques. Dr Gooding comments on the promise of this panel for use in clinical practice. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
